Grant: CIHR Fellowship
Direct Payment
$150,000.00
Functional corticostriatal plasticity in the transition to chronic pain
FY 2013-14
Summary
Chronic pain is a major worldwide health problem affecting an increasing number of people each year. The importance of this problem stems from the fact that the therapies currently available are limited and are often inefficient all the while inducing several side effects. Moreover, chronic pain diagnosis is always made when the chronicity is already present. In a cohort of patients who have suffered from similar episodes of back pain, Dr Apkarian's laboratory has recently demonstrated the possibility of detecting which individuals will develop chronic low back pain and which ones will recover. They showed that a specific connection between two regions of the brain, named medial prefrontal cortex (mPFC) and nucleus accumbens (NAc), provide paramount informations to predict either chronic pain development or recovery. This discovery changes the paradigm from: "managing chronic pain" to "treating pain before it becomes chronic", and pushes forward the possibility of blocking the chronification process. The economic burden caused by chronic pain patients could then be eased following the application of this new knowledge. In the project presented here, we will search for specific molecules implicated in the modulation of connectivity between mPFC and NAc. We will then evaluate the capacity of currently available compounds to positively influence this connectivity and hopefully block the transition from acute to chronic pain in patients that are predisposed to developing chronic pain. The results obtained from this study will thus be rapidly applicable in clinic because we will use safe and already approved drugs instead of new and un-sanctioned compounds.
Department
Program
CIHR Fellowship
Recipient
Location
Illinois, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
300749
Name
Tétreault Pascal G
Region
Illinois
Country
United States of America
Orgtype
Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Functional corticostriatal plasticity in the transition to chronic pain
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cerveau; Cortex Préfrontal; Douleur Chronique; Douleur Lombaire; Douleur Neuropathique; Imagerie Par Résonance Magnétique; Noyeau Accumbens
Abstract
Chronic pain is a major worldwide health problem affecting an increasing number of people each year. The importance of this problem stems from the fact that the therapies currently available are limited and are often inefficient all the while inducing several side effects. Moreover, chronic pain diagnosis is always made when the chronicity is already present. In a cohort of patients who have suffered from similar episodes of back pain, Dr Apkarian's laboratory has recently demonstrated the possibility of detecting which individuals will develop chronic low back pain and which ones will recover. They showed that a specific connection between two regions of the brain, named medial prefrontal cortex (mPFC) and nucleus accumbens (NAc), provide paramount informations to predict either chronic pain development or recovery. This discovery changes the paradigm from: "managing chronic pain" to "treating pain before it becomes chronic", and pushes forward the possibility of blocking the chronification process. The economic burden caused by chronic pain patients could then be eased following the application of this new knowledge. In the project presented here, we will search for specific molecules implicated in the modulation of connectivity between mPFC and NAc. We will then evaluate the capacity of currently available compounds to positively influence this connectivity and hopefully block the transition from acute to chronic pain in patients that are predisposed to developing chronic pain. The results obtained from this study will thus be rapidly applicable in clinic because we will use safe and already approved drugs instead of new and un-sanctioned compounds.
Competitiondate
201311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Tétreault, Pascal G
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~